Taken together, our results suggest that disrupting the CXCL14/CCR7/STAT3 signaling axis, both in vitro and in vivo, enhances DNA damage and increases cisplatin sensitivity in bladder cancer. This evidence concerns the gene CXCL14 and urinary bladder carcinoma.